Efficacy of adalimumab for the treatment of noninfectious uveitis in a real world setting

This study was aimed at assessing the long-term ocular control of Adalimumab (ADA) in a large real-world population with noninfectious primary or secondary uveitis, focusing on the steroid-sparing effect and on disease-modifying antirheumatic drugs (DMARDs) cotreatment. In the post hoc analysis we compared the efficacy of ADA in noninfectious anterior uveitis (AU) and posterior segment (PS) involvement, associated with different conditions, with a focus on Behçet’s syndrome (BS). The systematic review aimed to summarize current evidence on the efficacy and the safety of non-anti-TNFalfa biologic agents in adult patients with noninfectious uveitis associated with systemic inflammatory diseases.